As of 12:31 PM on the 24th, Seegene is trading at 129,000 KRW, down 1.38% from the previous day. The trading volume is 576,092 shares, which is about 26.56% of the previous day's volume. Seegene is known as a company that develops, manufactures, and sells molecular diagnostic reagents.
On February 19, Minjeong Seon, a researcher at Hana Financial Investment, stated, "In early February, a multiplex diagnostic kit was developed that can detect infection of four new types of novel variants of the COVID-19 virus?including the original strain, as well as variants from the UK, South Africa, and Japan/Brazil?in a single test, allowing confirmation of variant virus infection within two hours. A COVID-19 saliva diagnostic kit was developed, and recent research results show approximately 96% accuracy compared to the existing nasopharyngeal swab method. Continuous growth of Seegene is expected." She set Seegene's target price at 315,000 KRW.
Over the past five days, individual investors have net purchased 12,7313 shares of Seegene, while foreign investors and institutions have net sold 67,915 shares and 71,786 shares, respectively.

※Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
